EDG-7500 Achieves Major Milestones in CIRRUS-HCM Trial: Edgewise Demonstrates Clinical Promise Across HCM Variants

Edgewise Therapeutics, Inc. (EWTX) has successfully advanced its lead candidate EDG-7500 through critical stages of clinical evaluation, completing Parts B and C of the Phase 2 CIRRUS-HCM investigation while releasing encouraging safety interim findings from Part D. This represents a significant inflection point for the biotech company’s approach to treating hypertrophic cardiomyopathy, a prevalent inherited cardiac disorder.

Understanding the Clinical Need

Hypertrophic cardiomyopathy presents a substantial medical challenge, affecting approximately 1 in 500 individuals globally and representing the most prevalent genetic heart disease. Patients face heightened vulnerability to heart failure, dangerous arrhythmias, and sudden cardiac death. Existing pharmacological interventions impose considerable risk profiles, particularly systolic dysfunction concerns, highlighting the urgent requirement for therapeutically safer options. EDG-7500, designed as a cardiac sarcomere modulator available in oral form, targets early contraction velocity reduction while enhancing cardiac relaxation—all without compromising systolic performance metrics.

Trial Progression and Efficacy Signals

The CIRRUS-HCM investigation has demonstrated sequential progress across distinct patient populations. Part A, concluded in April 2025, revealed robust findings within a four-week assessment window: patients experienced rapid and clinically significant LVOT gradient reductions alongside meaningful patient-reported outcome improvements, complemented by favorable biomarker shifts while preserving left ventricular ejection fraction stability.

Part B enrolled the obstructive HCM subset and showed dose-dependent therapeutic responses. EDG-7500 treatment produced measurable improvements across multiple clinical parameters: NT-proBNP reduction, Kansas City Cardiomyopathy Questionnaire score advancement, New York Heart Association functional class improvement, and meaningful left ventricular outflow tract gradient amelioration.

Part C focused on non-obstructive HCM phenotypes, where EDG-7500 demonstrated reductions in NT-proBNP coupled with diastolic function improvements, validating its therapeutic applicability across distinct HCM manifestations.

Safety Profile Emerges as Differentiation Point

Interim Part D data has become particularly significant for competitive positioning. The ongoing 12-week assessment revealed EDG-7500 demonstrated strong tolerability, with no clinically meaningful left ventricular ejection fraction decline—a key safety advantage compared to alternative cardiac myosin inhibitors. Continuous cardiac monitoring detected zero atrial fibrillation events. This safety envelope, reducing monitoring burden intensity to approximately 0.71 of comparative agents’ requirements, could substantially expand eligible patient populations if regulatory approval is secured.

Timeline and Market Implications

Edgewise expects full Part D results delivery during 2026’s second quarter, with Phase 3 trial initiation targeted for year-end. The company has emphasized that systolic function preservation could meaningfully reduce clinical surveillance demands and broaden patient accessibility upon approval.

EWTX stock has fluctuated between $10.60 and $30.48 over the preceding 12 months. Current pre-market trading reflects investor optimism, with shares moving at $22.75, representing a 4.62% gain.